Tort Maria J, Emir Birol, Nguyen Jennifer L, Malhotra Deepa, Kim Chai Hyun, Snow Vincenza T
Medical Development & Scientific/Clinical Affairs, Pfizer Vaccines, 500 Arcola Road, Collegeville, PA, 19426, USA.
Pfizer Inc., 66 Hudson Boulevard East, New York, NY, 10001-2192, USA.
Adv Ther. 2025 Sep 15. doi: 10.1007/s12325-025-03343-z.
Continuous positive airway pressure (CPAP) is the first-line therapy for obstructive sleep apnea (OSA). We sought to understand whether CPAP prescription among adults diagnosed with OSA was associated with a higher likelihood of pneumonia diagnosis and inpatient hospitalization for pneumonia after adjusting for patient demographic characteristics and comorbidities.
This retrospective cohort study used de-identified data from the Optum Clinical Electronic Health Record (EHR) database for the time period January 2012 to December 2019. The study population comprised adults with an OSA diagnosis with and without CPAP prescription after the initial diagnosis. The primary outcome of interest was a pneumonia diagnosis in the first year following OSA diagnosis. Propensity score matching was used to balance the cohorts. Logistic regression was used to estimate the odds of developing pneumonia.
There were 328,340 patients with an OSA diagnosis and evidence of CPAP prescription and 964,199 patients with an OSA diagnosis without evidence of CPAP prescription. After 1:1 propensity score matching, 326,145 were included in each cohort. The risk of pneumonia in any setting and in the inpatient setting was higher among patients with CPAP prescription, odds ratio (OR), 1.06 (95% CI: 1.03, 1.09) and 1.24 (95% CI, 1.20, 1.29), respectively. The odds of developing pneumonia increased in any setting when CPAP was initiated on the date of OSA diagnosis (OR = 1.68, 95% CI: 1.62-1.72) among all patients, for patients aged 65 + years (OR = 1.68, 95% CI: 1.47, 1.92), patients with obesity (OR = 1.59, 95% CI: 1.47, 1.72), and patients with a history of pneumonia (OR = 1.68, 95% CI: 1.41, 2.00).
This study indicates that among patients with OSA, CPAP initiation was associated with incident pneumonia, particularly inpatient pneumonia hospitalizations. Longer CPAP prescription, older age, obesity, and previous history of pneumonia further increased the risk of incident pneumonia associated with CPAP prescription.
持续气道正压通气(CPAP)是阻塞性睡眠呼吸暂停(OSA)的一线治疗方法。我们试图了解,在调整患者人口统计学特征和合并症后,被诊断为OSA的成年人中,CPAP处方是否与肺炎诊断及因肺炎住院的可能性更高有关。
这项回顾性队列研究使用了Optum临床电子健康记录(EHR)数据库中2012年1月至2019年12月期间的去识别数据。研究人群包括初次诊断后有和没有CPAP处方的OSA诊断的成年人。感兴趣的主要结局是OSA诊断后第一年的肺炎诊断。倾向评分匹配用于平衡队列。逻辑回归用于估计发生肺炎的几率。
有328340例诊断为OSA且有CPAP处方证据的患者,以及964199例诊断为OSA但无CPAP处方证据 的患者。在1:1倾向评分匹配后,每个队列纳入326145例。有CPAP处方的患者在任何情况下和住院情况下发生肺炎的风险更高,比值比(OR)分别为1.06(95%CI:1.03,1.09)和1.24(95%CI,1.20,1.29)。在所有患者中,当在OSA诊断当天开始使用CPAP时,在任何情况下发生肺炎的几率都会增加(OR = 1.68,95%CI:1.62 - 1.72),65岁及以上的患者(OR = 1.68,95%CI:1.47,1.92),肥胖患者(OR = 1.59,95%CI:1.47,1.72),以及有肺炎病史的患者(OR = 1.68,95%CI:1.41,2.00)。
这项研究表明,在OSA患者中,开始使用CPAP与新发肺炎有关,尤其是住院肺炎。更长时间的CPAP处方、年龄较大、肥胖和既往肺炎病史进一步增加了与CPAP处方相关的新发肺炎风险。